0000914260-14-000094.txt : 20141126 0000914260-14-000094.hdr.sgml : 20141126 20141126080918 ACCESSION NUMBER: 0000914260-14-000094 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20141126 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141126 DATE AS OF CHANGE: 20141126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRO MED INC /NEW/ CENTRAL INDEX KEY: 0000008146 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER PERIPHERAL EQUIPMENT, NEC [3577] IRS NUMBER: 050318215 STATE OF INCORPORATION: RI FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13200 FILM NUMBER: 141251515 BUSINESS ADDRESS: STREET 1: 600 E GREENWICH AVE CITY: WEST WARWICK STATE: RI ZIP: 02893 BUSINESS PHONE: 4018284000 MAIL ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 FORMER COMPANY: FORMER CONFORMED NAME: ATLAN TOL INDUSTRIES INC DATE OF NAME CHANGE: 19850220 8-K 1 astromed-8k112614.htm ASTRO-MED 8-K 11 26 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
______________
FORM 8-K
______________

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED)
November 26, 2014
______________
ASTRO-MED, INC
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
______________
COMMISSION FILE NUMBER                0-13200

RHODE ISLAND
05-0318215
 
(STATE  OR OTHER
JURISDICTION OF 
INCORPORATION OR
ORGANIZATION)
(IRS EMPLOYER
IDENTIFICATION NUMBER)
600 EAST GREENWICH AVENUE, WEST WARWICK, RI 02893
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)
(401-828-4000)
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)





ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 26, 2014, Astro-Med, Inc. (the "Registrant") announced its unaudited financial information related to third quarter consolidated earnings for the quarter ended November 1, 2014.  A copy of the press release relating to such announcement, dated November 26, 2014, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS
(c)            Exhibit
Exhibit no.                          Exhibit
99.1
Press Release dated November 26, 2014



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.

DATE: November 26, 2014
ASTRO-MED, INC.
   
   
   
 
By:  /s/ Joseph P. O'Connell 
 
Joseph P. O'Connell
 
Senior Vice President,
Treasurer and Chief Financial Officer


INDEX TO EXHIBITS
 
Exhibit No.
Exhibit
   
99.1
Press Release Dated November 26, 2014
 




EX-99.1 2 ex99-1.htm EXHIBIT 99.1 PRESS RELEASE

 

Contact:

Joseph P. O'Connell
Senior Vice President, Chief Financial Officer
(800) 343-4039



Astro-Med Reports Strong Results for Third Quarter Fiscal 2015;
Board of Directors Declares Regular Cash Dividend

·
Net Sales of $23.1 Million, Up 27.3% from Q3 FY 2014
·
Gross Margin of 43.9%, Up 340 Basis Points from Q3 FY 2014
·
Operating Margin of 11.1%, Up 460 Basis Points from Q3 FY 2014
·
Diluted EPS of $0.20, Up from $0.14 in Q3 FY 2014
·
Company Completes Integration of Miltope Acquisition


WEST WARWICK, R.I., November 26, 2014 -- Astro-Med, Inc. (NASDAQ: ALOT), a leading manufacturer of specialty high-tech printing systems and data acquisition products, today reported net sales of $23.1 million for the three months ended November 1, 2014, an increase of 27.3% from the same period a year earlier. Net income for the fiscal third quarter of 2015 was $1.6 million, or $0.20 per diluted share, compared with net income of $1.1 million, or $0.14 per diluted share, for the same period a year earlier.
"By concentrating on three key areas – product development, manufacturing efficiency and geographic expansion – we are achieving increasing levels of operational and financial success," said Astro-Med President and Chief Executive Officer, Gregory A. Woods. "Our third-quarter performance reflected these efforts.  Solid demand across all product lines generated record third-quarter net sales, as our QuickLabel Systems (QLS) and Test & Measurement (T&M) segments increased approximately 22% and 39%, respectively. Both our domestic and international sales channels contributed nicely to the Company's top-line growth."

"Higher revenue, combined with the success of our ongoing lean manufacturing initiatives, contributed to a 340 basis-point increase in our gross margin, which grew to 43.9% in the quarter," Woods said. "Even as we stepped up investments in marketing and R&D, our operating profit increased to $2.6 million, or 11.1% of net sales, from $1.2 million, or 6.5% of net sales, in the third quarter of fiscal 2014. This demonstrates continued improvement in our operating leverage."
For the nine months ended November 1, 2014, Astro-Med reported net sales of $66.3 million, an increase of 30.3% over the prior year sales of $50.9 million for the same period.  The Company reported net income of $4.1 million, or $0.52 per diluted share, for the first nine months of fiscal 2015 compared with $1.4 million, or $0.18 per diluted share, for the same period of fiscal 2014. The fiscal 2014 results included a reserve established to address a non-compliant component in a limited number of ToughWriter Printers. The after-tax cost of this reserve was equal to $0.06 per diluted share. Excluding the impact of this reserve, the Company's net income on a non-GAAP basis for the nine months ended November 2, 2013 was $1.8 million, or $0.24 per diluted share.

At November 1, 2014, Astro-Med had cash and cash equivalents totaling $30.9 million, compared with $27.1 million at January 31, 2014.
 
Recent Highlights:
·
New QLS Products – Astro-Med launched the industry's first full line of color digital label printers using pigment-based ink for ultra-durable labels. Three printer models – the Kiaro! D, Kiaro! 200D and Kiaro! 50D – were unveiled at PACK EXPO International 2014, the largest packaging and processing trade show in North America. The printers are designed for non-laminated industrial labels that will be exposed to sunlight, chemicals, moisture, dirt or other harsh conditions that would otherwise test their legibility and color fastness. The Company also introduced the Kiaro! 50, a narrow-format digital color label printer specifically designed for labels sized 1" to 2.16" wide.
·
Aircraft Printer – Hong Kong-based Cathay Pacific Airways selected Astro-Med's NP4840 network printer for its eEnabled Aircraft program.
·
Miltope Integration Complete – Astro-Med completed the integration of the Miltope acquisition in the third quarter as planned. Manufacturing for Miltope's aerospace printer line has been fully transitioned from Alabama to Astro-Med's manufacturing facility in West Warwick, RI.
·
Expansion of Direct Sales in Asia – Tapping into what is considered a significant area for growth, Astro-Med achieved its goal of expanding into Southeast Asia with the opening of a Malaysia office in the third quarter. Further expansion in the Asia Pacific region is planned for the fourth quarter of fiscal 2015.
Board of Directors Declares Regular Quarterly Dividend
On November 24, 2014, the Directors of Astro-Med, Inc. declared a regular quarterly cash dividend of $0.07 per share. The dividend, which represents a cash dividend of $0.28 per share on an annualized basis, is payable January 2, 2015 to shareholders of record on December 19, 2014.
Business Outlook
"We will continue to drive AMI's strategy of global growth, expanded distribution, and productivity improvement in the final quarter of fiscal 2015 and beyond.  However, given the uncertainty evident in certain European markets, coupled with the upcoming final stage of our Oracle ERP conversion, we are facing some additional headwinds in our fourth quarter," Woods said.  "Notwithstanding these issues, both of our segments are increasing their competitive positions in the market.  In the QLS segment, our new pigment ink-based and narrow-format technologies continue to raise the bar for quality, performance and cost efficiency. Within the T&M segment, demand for our ruggedized aerospace printers is strong in both the airline-direct and OEM markets, and our established data acquisition technology continues on a growth path."

Q3 Fiscal 2015 Conference Call
The third-quarter fiscal 2015 financial results conference call will be held today, Wednesday, November 26, 2014 at 9:00 a.m. EST. It will be broadcast in real time on the Internet through the "Investors" section of the Company's website at www.Astro-MedInc.com. You also may participate in the conference call by dialing 888-466-4440 (U.S. and Canada) or 719-457-2704 (International) with passcode 393116.
Following the live broadcast, an audio webcast of the call will be available at www.Astro-MedInc.com. A telephone replay of the conference call will be available for seven days by dialing 888-203-1112 (U.S. and Canada) or 719-457-0820 (International) with passcode 8012121.
About Astro-Med, Inc.
Astro-Med, Inc. is a leading manufacturer of specialty high tech printing systems and data acquisition systems. Products include color label printers and consumables sold under the QuickLabel Systems brand as well as ruggedized printers for aerospace, defense applications, and data acquisition products sold under the Astro-Med brand. Astro-Med, Inc. is a member of the Russell Microcap® Index. Additional information is available by visiting www.Astro-MedInc.com.
Forward-Looking Statements
Information included in this news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, but rather reflect our current expectations concerning future events and results. These statements may include the use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "continues," "may," "will," and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning growth through acquisitions, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties, and factors include, but are not limited to, those factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2014 and subsequent filings Astro-Med makes with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reader is cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this news release.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release also contains the Non-GAAP financial measures, Non-GAAP net income and diluted EPS. The Company believes that the inclusion of these non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of changes in the Company's core operating results, and also can help investors who wish to make comparisons between Astro-Med and other companies on both a GAAP and a non-GAAP basis. Astro-Med's management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring its core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. These measures are also used by the Company's management to assist with their financial and operating decision making.

 

 
ASTRO-MED, INC.
Consolidated Statements of Operations In Thousands Except for Per Share Data
(Unaudited)
 
                 
  
 
Three-Months Ended
   
Nine-Months Ended
 
   
November 1, 2014
   
November 2, 2013
   
November 1, 2014
   
November 2, 2013
 
                 
Net Sales
 
$
23,137
   
$
18,179
   
$
66,277
   
$
50,858
 
Cost of Sales
   
12,985
     
10,816
     
37,901
     
30,796
 
Product Replacement Related Costs
   
-
     
-
     
-
     
672
 
                                 
Gross Profit
   
10,152
     
7,363
     
28,376
     
19,390
 
     
43.9
%
   
40.5
%
   
42.8
%
   
38.1
%
Operating Expenses:
                               
   Selling and Marketing
   
4,606
     
3,727
     
13,483
     
10,680
 
   Research and Development
   
1,564
     
1,230
     
4,414
     
3,617
 
   General and Administration
   
1,407
     
1,223
     
4,041
     
3,745
 
     
7,577
     
6,180
     
21,938
     
18,042
 
                                 
Operating Income
   
2,575
     
1,183
     
6,438
     
1,348
 
     
11.1
%
   
6.5
%
   
9.7
%
   
2.7
%
                                 
Other Expense, Net
   
(46
)
   
(2
)
   
(85
)
   
(64
)
                                 
Income from Continuing Operations Before Taxes
   
2,529
     
1,181
     
6,353
     
1,284
 
Income Tax Provision for Continuing Operations
   
974
     
436
     
2,235
     
446
 
Income from Continuing Operations
   
1,555
     
745
     
4,118
     
838
 
Income from Discontinued Operations, Net of Taxes
   
-
     
363
     
-
     
517
 
                                 
 Net Income
 
$
1,555
   
$
1,108
   
$
4,118
   
$
1,355
 
                                 
Earnings Per Share – Basic:
                               
     Net Income per share from Continuing Operations
 
$
0.20
   
$
0.10
   
$
0.54
   
$
0.11
 
     Net Income per share from Discontinued Operations
   
-
     
0.05
     
-
     
0.07
 
     Net Income per share - Basic
 
$
0.20
   
$
0.15
   
$
0.54
   
$
0.18
 
                                 
Earnings Per Share – Diluted:
                               
     Net Income per share from Continuing Operations
 
$
0.20
   
$
0.10
   
$
0.52
   
$
0.11
 
     Net Income from Discontinued Operations
   
-
     
0.04
     
-
     
0.07
 
     Net Income per share - Diluted
 
$
0.20
   
$
0.14
   
$
0.52
   
$
0.18
 
                                 
Weighted Avg Number of Common Shares  - Basic
   
7,730
     
7,490
     
7,678
     
7,449
 
Weighted Avg Number of Common Shares  - Diluted
   
7,926
     
7,716
     
7,897
     
7,650
 
                                 
Dividends Declared Per Common Share
 
$
0.07
   
$
0.07
   
$
0.21
   
$
0.21
 
                                 





Selected Balance Sheet Data
 
in Thousands
 
(Unaudited)
 
         
   
As of
   
As of
 
   
November 1, 2014
   
January 31, 2014
 
Cash & Marketable Securities
 
$
30,903
   
$
27,107
 
Current Assets
 
$
69,010
   
$
65,034
 
Total Assets
 
$
81,753
   
$
77,964
 
Current Liabilities
 
$
10,569
   
$
9,892
 
Shareholders' Equity
 
$
70,095
   
$
66,614
 
                 





Reconciliation of Non-GAAP Adjustments in Thousands
(Unaudited)
 
 
   
Three-Months Ended
   
Nine-Months Ended
 
   
November 1, 2014
   
November 2, 2013
   
November 1, 2014
   
November 2, 2013
 
GAAP based results as reported:
               
                 
Net Income
 
$
1,555
   
$
1,108
   
$
4,118
   
$
1,355
 
                                 
Non-GAAP adjustments:
                               
                                 
Product Replacement Costs
   
-
     
-
     
-
     
423
 
                                 
Non-GAAP Net Income
 
$
1,555
   
$
1,108
   
$
4,118
   
$
1,778
 
                                 
GAAP based results as reported:
                               
EPS -diluted
 
$
0.20
   
$
0.14
   
$
0.52
   
$
0.18
 
Non-GAAP adjustments:
                               
                                 
Product Replacement Costs
   
-
     
-
     
-
     
0.06
 
                                 
Non-GAAP EPS - diluted
 
$
0.20
   
$
0.14
   
$
0.52
   
$
0.24
 

 


GRAPHIC 3 image00001.jpg begin 644 image00001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"``<`3,#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#$FU._FE>6 M6]NGDXP:P[.$7-Y!` MTB1++(J&1V`503C))Z`5[?\`%&;PY?\`@%+/3=6TV2?3MC6\<=RA8A1M*@`\ M\']*^QQ%7V52G!+1O70_/\+0]O2J5)2U2TUZ_P##%;X?>%M"UGPI9WVK7]TM MY(7WC[<4Z,0.,\<5S.BZ;;W'Q<_L0W%S-I2SR*$-PQW*J%@"0>>17H/PFT#2 M+[P)I]Q>:793SL7W22P*S'YSU)%<7X<@AM?CV\%M$D4,=Q.J(BX51Y3<`5YT M*K=%*GAFXK5QOY^IZW_PA7A__H'C_O[)_P#%4?\`"%>'_P#H M'C_O[)_\57145XGMZO\`,_O/HOJU'^1?:ZGXI_\ MB=-_U\VW_HY*ZPHI8,5!8=#CD5U1Q#C34I:MM_H<<\+&=:48:))/;3J5=(-R M=*LS?#%V84\T?[>!G]:X+XS^,)M`TV"PTR=H=2NCO\Q.L<8/)^I/'YUZ'>7, M5G:37-RX2&%#(['H%`R37R?XJUF?Q1XFN;^0[?M$@2)6.`B9PH]N.OXUKEF& M5>JYR7NHPSC&/#4%3@_>EI\NK+L7C[Q1'*CMK5VP5@2I88.#TZ5]16=PEU9P M7$?W)HUD7Z$9%?*7C:PL]-\0S6FG3Q7%M'%$!)$P96/EKN.1_M9KW/PMKTZ? M!Z+4K1#-=VEFZ!<9^9,J,C\`:Z\SH1G3ISIJU_EN<.38F<*M6G6DW97[[;V. M[N+F"W`-Q-%$#W=PO\ZB^&_#\:_#OQ-/H.HIJ5Q.!$=I,0BB4AF+*W1B`3WZ#!KGK97&C%SUF_MK.SL'MX9WCC9PQ)`)&3@^U>P MZ-?- M@:#H.C:BH2\!GNI4#AL%F"KR/9!7;B;UXJI5J)R2^Y:[ M;?U8^FO/AVLWFQ[5Y8[A@?6G12)-&LD3JZ-T93D'\:^2M$T;7-7L[I-&L[JY MME(:81?=)'3/J>O%=5XW\4W^G:?8^%M-FDM;>QMHX[IHSM:24J"RD]0`3T]< MUQSRGWU"$[OKY([X9[>FZE2FTNGF_+0^A6O;19?*:Y@$O]PR#/Y58KY+U'PM MJUAH%KK=Y;A+&Z8!'+@L<@D$CJ,X->E_`OQ->R'4M,OIY)[6VM_M,1D))C`. M"N3VY!Q[5-?+%3I.I3GS6W-,+G+JUE1JT^6^W]6/::*\9/QO7)QH;$=O](_^ MQKLM'\;C4?`E]XCEM?LB0"39&7W;BHXYP.I.*Y*F!KTDG.-KZ=#MI9GAJS:A M*]E?9[(\P^)7CO6$\8WUOH^ISVUG;$0A8B`"P^\?SR/PKJO@SXJO+_3]=EU[ M4)9UM`DV^4_<3#9_E7B^GVMQK.I.BY>>023N?7"EV/Z&I--UB>PTG5+*#A=0 M6-)&]%5BOR/6)YXH$WSRI$OJ[!1^M+#-%. MF^&1)%]48$?I7R:^I-XAUL3>*-5N$B?)>8(9-OH%3.!3=`UZ[\-:T+K2+MS$ MDG(Y59DS_$ON/RKE_L9\ME+WO33[SM7$,>9-P]WUU^X^MR0!D]*Q_$.IP0>' M-6NH9XY#;VTC'8P.TA3Z5Y+\;?%]S+=0Z)8RO!;^2LUSM."Y89"D^@&#^-<# M!HFMV'AEM>A#0:9<9MF=9,&13E2"O=H22RK>1VS M>7)(,/R=L;'_`&B"I^M>-^$O%GB?5/$^E64FMWC1S7*(XW=5SS^F:]0^.]Y] MG\#&$'!N;B./'J!EO_917EWP5L_M7Q`LW(RMO')-^.W`_P#0J,%""PM2M**Z M_D&85*CQM+#PD[:)Z^?^1])-/"K%6EC!'4%A39;JWA56FGBC#_=+.!GZ5\F^ M,[L7_BS6+K.1)=28/L#@?H!2>)K/5;&[MX-<+><+>-HD+A@D9'R@`<#@=*B. M3I\MY[^7_!-)\0-+KSP]\(&NB_F7)NWM;+S#G;P#GZ#YN*\^T?2M;\;ZU*D#O=WA4R22SR<*,] M23[]A6-/*VW)SE:,7:YT5U_#_@G1'&XF23]C^/_``#EO!%I M<^&_%*WFMZ!JEPML'58HK8M\YXR<\$8S^E>F3^.].GADBD\'ZV4=2K?Z"O0C M'K7IM%.MCHUY<\X:^K)P^6SPT/9TZFG^%,\?\#^,1X<\.6^F2^'M?E:%GPZ6 MO!!8D=3UP17,:5>W,/Q3/B.;1]62Q>>1ROV5BZAD*\@#WKZ'HH6.A%RDH:RO M?7N$LMG*,(NII"S6G;YG)?\`">Z7_P`^FL?^"^7_``H_X3W2_P#GTUC_`,%\ MO^%=;17+STOY7]__``#MY*_\Z^[_`()YOXO\10^(])32M*L-5DNI[F`CS+-X MU4+(K$EB,`8!KTBBBIJ5%**C%62_7_ABJ5*49.XDAB9@$!X7(]3^@]Z\Q\)?#C6?$$MRLL;Z:D(!WW43#>3V`KZ M:HKLH9C*A2]G35GW.#$Y3#%5_;59-KL?+_BKX?ZSH.H1VT4$NH*\8D\VVA8J M.2,'WXKI?#4_BO2_AW?Z?I6E:A'=_:PPD$1#1QE025!Y)RN.!W->]T5I/-95 M(*-2*=C*GDD*4W.E-JZ:^_S/E;5(M>U^:")]`*W29!>VL#$TI/=\#!_2O2-! M\*:GX6^&7B!YXG?5-0B"BVB&]D'W0..I^8DXKV&BIJYG*<5!122=_P!2J&30 MI2=24VY--7[75CYH^'?AC53XVT=KO3+R&WCF$K/)"RJ-H)Y)'J*UOC+IVK:I MXXG>TTV]GMX88XD>.%F4\;C@@>K&OH&BJ>:2=95N796)62P6'=!3>KO?]#B? M@[I&XEDDE='7:PR<#(^@%>:?%?P+JT/B.\U73[66\L;M_-)A7 M-@D?XD`?G7M'PT\`_P#"/Z->C56#7VH1^7,(V_U<>#\H/KSR?\*] M#HK3$YE.M'DBE%>1EA,HIX>?M)2LT5C#&U5-2FW*VMFSIJ9?1=.4*:46U: MZ70\+^"OA6[&L:E=:I97%LB6IAC\Z,IDOP<9Z\`_G7(^'?`VK:CXEM]/N;"[ MM[4RD2S/$54(IYY/J!Q]:^HJ*Z?[5J*4II?%;Y6.+^PZ3A"#?PMOUN?/GQ@T M34;GQCMTW3+N6T@M8HHS#"S*`!T!`[5T6E^$K_6O@U%I@B>WU"*=IXXIP4+$ M,>#GID$U[#14/,9^SA!+X;._H:QRFFJLZK=^=-6]3Y:T>'7?"VI7!E\/-/.\ M1BV7=F957)!#+QC/%=WX%T7Q5K%_#-J]E8V6F(P9S+IT*O(/[JC;D9]:]JHJ MZV9NHG[B3?73QDU]244Z>:SA",'%. MQ-;(Z=2I*HIMZBB%KN24PEVP<(`#@>F2>?H*ZE73I3QPM\_G<]1Y7%XGZSS:KI\K' MRAIGA?6[O5[1)]*OT6:=`[M`P`!89).*Z+XJ:7J^I>.=0EM=+O9+=-D4;I`Q M4A5'0X]-7O@G4-0^$&CV MMI"PU&V